Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Subscribe To Our Newsletter & Stay Updated
